Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

Dr Matthew McKinney reflects on his first experience of treating DLBCL and highlights the advancements in emerging treatments ...

Dr Matthew McKinney reflects on the mentorship and diverse experiences that shaped his philosophy toward patient care and ...

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and ...

Patients were stratified by CD30 expression (positive [≥1%] v negative [<1%]), cell of origin (germinal center B cell or non–germinal center B cell), previous treatment with CAR T-cell therapy ...

During a recent interview with ABC WXYZ in Detroit, Dave Coulier's wife, Melissa, said that while the “Full House" alum's ...

Fuller House actor Dave Coulier is currently battling stage 3 cancer. Stage 3 cancer is a fairly advanced form of cancer but ...

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s ...

Panelists discuss key strategies for preventing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients receiving bispecific therapies for B-cell ...

The second indigenous CAR-T cell therapy, Qartemi, has been approved by India's drug regulator. Qartemi is a "living drug" ...

An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer ...